Orchestra BioMed Announces Promising Clinical Data for AVIM Therapy in Treating Hypertension and Diastolic Dysfunction
Reuters
Aug 14
<a href="https://laohu8.com/S/OBIO">Orchestra BioMed</a> Announces Promising Clinical Data for AVIM Therapy in Treating Hypertension and Diastolic Dysfunction
Orchestra BioMed Holdings Inc. has announced the publication of clinical data in JACC: Advances, revealing the potential benefits of their AtrioVentricular Interval Modulation (AVIM) therapy for patients with hypertension and diastolic dysfunction. The data, derived from a retrospective, treatment-blinded analysis of the MODERATO II study, indicates that AVIM therapy significantly reduced systolic blood pressure in both office and ambulatory settings, while also improving echocardiographic markers of diastolic dysfunction. These findings underscore the therapy's promise in addressing components that contribute to heart failure with preserved ejection fraction (HFpEF). The results were previously presented in a late-breaking session at the 2025 Technology and Heart Failure Therapeutics Meeting and are now accessible in the journal. The AVIM therapy is currently under evaluation in the BACKBEAT global pivotal study, conducted in association with Medtronic, aiming to secure U.S. regulatory approval for pacemaker-indicated patients with uncontrolled hypertension.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Orchestra Biomed Holdings Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9512336-en) on August 14, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.